Zacks: Brokerages Anticipate Teva Pharmaceutical Industries Limited (TEVA) to Post $0.86 Earnings Per Share
Wall Street brokerages predict that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will post earnings per share (EPS) of $0.86 for the current quarter, according to Zacks. Five analysts have provided estimates for Teva Pharmaceutical Industries Limited’s earnings. The lowest EPS estimate is $0.73 and the highest is $1.25. Teva Pharmaceutical Industries Limited reported earnings of $1.38 per share in the same quarter last year, which would indicate a negative year over year growth rate of 37.7%. The company is scheduled to announce its next quarterly earnings results on Monday, February 12th.
On average, analysts expect that Teva Pharmaceutical Industries Limited will report full-year earnings of $3.89 per share for the current financial year, with EPS estimates ranging from $3.78 to $4.40. For the next year, analysts expect that the business will post earnings of $2.92 per share, with EPS estimates ranging from $2.50 to $4.07. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Teva Pharmaceutical Industries Limited.
A number of research analysts have recently weighed in on the company. TheStreet cut Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. ValuEngine cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Wednesday, October 25th. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, October 26th. Seven investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and an average target price of $21.88.
Teva Pharmaceutical Industries Limited (TEVA) traded up $0.25 during trading hours on Friday, reaching $13.33. The company’s stock had a trading volume of 14,414,329 shares, compared to its average volume of 15,458,282. The stock has a market capitalization of $13,820.00, a PE ratio of 3.20 and a beta of 0.52. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries Limited has a 1 year low of $10.85 and a 1 year high of $38.89.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. The ex-dividend date is Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 2.55%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -16.01%.
A number of hedge funds have recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries Limited during the 2nd quarter worth approximately $106,000. Kistler Tiffany Companies LLC increased its holdings in Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the 3rd quarter worth approximately $129,000. Finally, Cutler Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter valued at approximately $133,000. Institutional investors own 52.29% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/21/zacks-brokerages-anticipate-teva-pharmaceutical-industries-limited-teva-to-post-0-86-earnings-per-share.html.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.